| Literature DB >> 32807149 |
Luca Valko1, Szabolcs Baglyas2, V Anna Gyarmathy3,4, Janos Gal2, Andras Lorx2.
Abstract
BACKGROUND: It has been shown that home mechanical ventilation improves quality of life, but it has not been widely studied which particular patient groups benefit the most from starting this type of therapy. The purpose of this prospective observational study was to evaluate quality of life change patterns 6 months after initiation of home mechanical ventilation in patients suffering from chronic respiratory failure using patient reported outcomes.Entities:
Keywords: Chronic respiratory failure; Domiciliary ventilation; Home mechanical ventilation; Long term ventilation; Quality of life change
Mesh:
Year: 2020 PMID: 32807149 PMCID: PMC7433042 DOI: 10.1186/s12890-020-01262-z
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Studies utilizing SRI to report detailed HRQL for HMV patients
| Author | Study aim | Patients | Main HRQL (SRI SS) finding for HMV patients | |
|---|---|---|---|---|
| Windisch et al. [ | Studies reporting change in HRQL | HRQL improvement during HMV | 85 stable NIV patients | 49 ± 15 (baseline) 61 ± 15 (1 month) 61 ± 16 (1 year) |
| Struik et al. [ | NIV vs. standard treatment | 108 COPD patients after acute exacerbation | 47.9 ± 15.1 (baseline) 55.0 ± 15.4 (12 months) | |
| Murphy et al. [ | O2 therapy vs NIV + O2 therapy | 64 hypercapnic patients after acute exacerbation | 50.6 (6 weeks) | |
| Howard et al. [ | CPAP vs Bi-level PAP | 57 OHS patients (outpatient or hospital referral) | 50.63 ± 3.65 (baseline) 63.5 ± 3.74 (3 months) | |
| Storre et al. [ | AVAPS in OHS | 10 OHS patients starting NIV | 63 ± 15 (baseline) 78 ± 14 (6 weeks BPV-S/T) 76 ± 16 (6 weeks BPV-S/T-AVAPS) | |
| Murphy [ | Studies reporting HRQL for a specific HMV patient group | High intensity vs high pressure NIV | 7 COPD with established HMV | 57 ± 11 vs 69 ± 16 |
| Storre et al. [ | High intensity vs target volume NIV | 10 COPD patients with established HMV | 59.3 ± 14.8 vs 62.4 ± 18.9 | |
| Arellano-Maric et al. [ | NIV vs CPAP | 42 OHS patients with established NIV | 61.2 ± 16 vs 65.3 ± 14 | |
| Windisch [ | SRI validation in COPD | 162 COPD patients with established NIV | 52 ± 17 | |
| Walterspracher [ | SRI for LOT COPD patients | 42 COPD patients with established NIV | 53.2 ± 18.6 | |
| Oga et al. [ | HRQL tool comparisons | 56 COPD/TB patients with established NIV | 56.0 ± 15.3 | |
| Chen et al. [ | Chinese SRI validation | 149 stable NIV patients | 52.93 ± 15.11 | |
| Budweiser [ | Studies reporting HRQL for mixed HMV patient group | Prognostic value of HRQL | 231 stable IV and IV patients | 61.2 ± 17.7 (all patients) 52.2 ± 15.6 (COPD) 66.2 ± 17.2 (RCWD) 55.3 ± 9.2 (NMD) 71.3 ± 15.7 (OHS/OL) |
| Gosh et al. [ | English SRI validation | 152 stable NIV and IV patients | 55.9 ± 18.9 (all patients) 43.1 ± 17.3 (COPD) 61.9 ± 16.1 (RCWD) 58.8 ± 20.3 (NMD) 53.4 ± 18.8 (OHS) 53.5 ± 19.7 (miscellaneous) | |
| Oga et al. [ | Japanese SRI validation | 56 stable NIV patients | 56.0 ± 15.3 (all patients) 56.6 ± 14.7 (COPD) 55.5 ± 16.4 (Tb) | |
| Ribeiro et al. [ | Portuguese SRI validation | 93 stable NIV and IV patients | 56.6 ± 15.7 (all patients) 57.0 ± 16.5 (COPD) 55.6 ± 15.1 (OHS) 62.0 ± 12.6 (RCWD) 50.2 ± 16.2 (COPD+OSA) 59.4 ± 19.2 (NMD) 46.0 ± 13.3 (miscellaneous) | |
| Markussen et al. [ | Norwegian SRI validation | 127 stable NIV and IV patients | 55.8 ± 18.4 (all patients) 61.0 ± 14.7 (NMD) 43.2 ± 19.0 (COPD) 58.4 ± 18.3 (OHS) 55.8 ± 18.4 (RCWD) | |
| Valko et al. [ | Hungarian SRI validation | 104 stable NIV and IV patients | 66.8 ± 15.1 (NIV) 58.2 ± 13.6 (IV) | |
| Huttmann et al. [ | HRQL after unsuccessful weaning | 25 IV patients | 49 ± 16 (NMD) 47 ± 20 (COPD) | |
| Huttmann et al. [ | HRQL of invasively ventilated HMV patients | 32 IV patients | 53 ± 16 (all patients) 58 ± 16 (NMD) 48 ± 15 (lung diseases) | |
| Raveling et al. [ | Hypercapnia improvement as a survival predictor | 240 COPD patients starting NIV | 49.9 ± 15.0 (all patients) 54.6 ± 14.3 (stable patients) 47.9 ± 14.9 (patients after ARF) | |
Data are presented as mean (SD)
NIV noninvasive ventilation, IV invasive ventilation, HRQL health related quality of life, HMV home mechanical ventilation, SRI SS Severe Respiratory Insufficiency Questionnaire Summary Score, COPD chronic obstructive pulmonary disease, TB tuberculosis sequelae, OHS obesity hypoventilation syndrome, OL overlap syndrome, NMD neuromuscular disease, RCDW restrictive chest wall disease, BPV-S/T bilevel pressure ventilation -spontaneous/timed, AVAPS average volume assured pressure support
Baseline demographics and patient characteristics
| Characteristic | mean (SD) or n (%) |
|---|---|
| Total | 66 (100%) |
| Gender | |
| Female | 20 (30.3%) |
| Male | 46 (69.7%) |
| Age (years) | 51.5 (±18.1) |
| Initiation of ventilation | |
| Acute | 40 (60.6%) |
| Elective | 24 (39.4%) |
| Interface | |
| Invasive | 14 (21.2%) |
| Noninvasive | 52 (78.8%) |
| O2 supplementation need | |
| No | 33 (50%) |
| Yes | 33 (50%) |
| O2 flow (L/min) | 1.8 (±2.8) |
| Daily ventilation need (hours) | 12.6 (±6.5) |
| Ventilator settings | |
| Target volume (mL) | 541 (±129) |
| Inspiratory pressure (cmH2O) | 22.2 (±4.8) |
| Exspiratory pressure (cmH2O) | 8.3 (±3.6) |
| Frequency (/min) | 15.9 (±3.6) |
| Initial diagnosis | |
| Chronic obstructive pulmonary disease | 9 (13.6%) |
| Restrictive chest wall disease | 5 (7.6%) |
| Obesity hypoventilation syndrome | 20 (30.3%) |
| Non progressive neuromuscular disease | 19 (28.8%) |
| Progressive neuromuscular disease (amyotrophic lateral sclerosis) | 13 (19.7%) |
| Lung function | |
| FVC% | 47.2 (±22.2) |
| FEV1% | 38.7 (±21.3) |
| FEV1/FVC% | 86.0 (±21.8) |
| PEF% | 36.5 (±20.6) |
| Arterial blood gas | |
| paO2 (mmHg) | 69.7 (±14.2) |
| paCO2 (mmHg) | 49.7 (±17.5) |
| HCO3 (mmol/L) | 28 (±5.2) |
Data are presented as mean (SD) for continuous and as percentages (n) for categorical variables. Lung function parameters are presented as percentage of expected value
FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, PEF peak expiratory flow
Fig. 1Bar graphs of baseline scores of the SRI subscales for the whole study group, by interface and by diagnosis. Boxes represent means, error bars represent standard error. Significant differences are marked with asterisk. COPD: chronic obstructive pulmonary disease, RCWD: restrictive chest wall disease, OHS: obesity hypoventilation syndrome, NMD: neuromuscular disease, ALS: amyotrophic lateral sclerosis, RC: Respiratory complaints, PF: Physical functioning, AS: Attendant symptoms and sleep, SR: Social relationships, AX: Anxiety WB: Psychological well-being, SF: Social functioning, SS: Summary Score
HRQL subscale values before and 6 months after initiation of home mechanical ventilation
| Quality of life before home mechanical ventilation | Quality of life 6 months after initiation of home mechanical ventilation | ||
|---|---|---|---|
| RC | 58.3 (±25.9) | 78.7(±17.3) | |
| PF | 36.7(±22.5) | 42.8(±29.6) | |
| AS | 55.5(±20.6) | 74.8 (±14.0) | |
| SR | 74.1(±18.1) | 76.2(±18.4) | |
| AX | 63.3(±25.0) | 77.7(±22.6) | |
| WB | 57.5(±19.7) | 63.8(±19.3) | |
| SF | 58.7(±21.1) | 63.6(±24.6) | |
| SS | 57.7(±14.4) | 68.2(±15.8) |
Significant differences are marked with asterisk
RC Respiratory complaints, PF Physical functioning, AS Attendant symptoms and sleep, SR Social relationships, AX Anxiety, WB Psychological well-being, SF Social functioning, SS Summary Score
Fig. 2Bar graphs of changes in the scores of SRI subscales at the 6-month follow-up in the whole study group, by interface and by diagnostic groups. Boxes represent means, error bars represent standard error. Significant differences are marked with asterisk. COPD: chronic obstructive pulmonary disease, RCWD: restrictive chest wall disease, OHS: obesity hypoventilation syndrome, NMD: neuromuscular disease, ALS: amyotrophic lateral sclerosis, RC: Respiratory complaints, PF: Physical functioning, AS: Attendant symptoms and sleep, SR: Social relationships, AX: Anxiety WB: Psychological well-being, SF: Social functioning, SS: Summary Score
Fig. 3Bubble chart of SRI subscale changes for the whole study group and according to interface and diagnosis after 6 months of home mechanical ventilation. Size corresponds to value of change from baseline. Significant changes are marked with gray shading. Negative changes are marked by negative sign pattern. COPD: chronic obstructive pulmonary disease, RCWD: restrictive chest wall disease, OHS: obesity hypoventilation syndrome, NMD: neuromuscular disease, ALS: amyotrophic lateral sclerosis, RC: Respiratory complaints, PF: Physical functioning, AS: Attendant symptoms and sleep, SR: Social relationships, AX: Anxiety WB: Psychological well-being, SF: Social functioning, SS: Summary Score
Fig. 4Subscale changes in relation to baseline subscales. Scatterplot of SRI subscale changes according to initial SRI values. X axis shows change of SRI subscale. Y axis shows initial SRI subscale value. R2Linear: coefficient of determination, CC: correlation coefficient, RC: Respiratory complaints, PF: Physical functioning, AS: Attendant symptoms and sleep, SR: Social relationships, AX: Anxiety WB: Psychological well-being, SF: Social functioning, SS: Summary Score